Beth A. Pangallo

Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados et al. · The Lancet · 2018 · 349 citations · Full text

Inflammation, Rheumatology, Rheumatoid Disorder +14

A Randomized, Placebo-Controlled Study of Duloxetine for the Treatment of Children and Adolescents With Generalized Anxiety Disorder

Jeffrey R. Strawn, Apurva Prakash, Qi Zhang et al. · Journal of the American Academy of Child & Adolescent Psychiatry · 2015 · 108 citations

Generalized Anxiety Disorder, Psychiatry, Addiction +11

A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder

Graham J. Emslie, Apurva Prakash, Qi Zhang et al. · Journal of Child and Adolescent Psychopharmacology · 2014 · 105 citations · Full text

A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder

Sarah Atkinson, Apurva Prakash, Qi Zhang et al. · Journal of Child and Adolescent Psychopharmacology · 2014 · 77 citations

Long‐term safety profile of ixekizumab in patients with moderate‐to‐severe plaque psoriasis: an integrated analysis from 11 clinical trials

Richard G. Langley, Alexa B. Kimball, Himmet Nak et al. · Journal of the European Academy of Dermatology and Venereology · 2018 · 60 citations